NCT03721016

MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 415 (actual)
• Sponsor: Medy-Tox · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and efficacy of MT10109L for the treatment of glabellar lines (GL) with or without concurrent treatment of lateral canthal lines (LCL) in participants with moderate to severe GL and LCL.

Conditions

• Glabellar Lines
• Lateral Canthal Lines

Interventions

Type	Name	Description
DRUG	MT10109L	MT10109Lwill be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
DRUG	Placebo	Placebo will be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.

Timeline

• Start date: 2018-10-26
• Primary completion: 2020-03-05
• Completion: 2021-01-22
• First posted: 2018-10-26
• Last updated: 2023-05-25
• Results posted: 2023-04-21

Locations

21 sites across 4 countries: United States, Canada, Germany, United Kingdom

Regulatory

• FDA-regulated drug study